TY - JOUR AU - Ageno, W. AU - Gallus, A. S. AU - Wittkowsky, A. AU - Crowther, M. AU - Hylek, E. M. AU - Palareti, G. PY - 2012 DA - 2012// TI - Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines JO - Chest VL - 141 UR - https://doi.org/10.1378/chest.11-2292 DO - 10.1378/chest.11-2292 ID - Ageno2012 ER - TY - JOUR AU - Garcia, D. A. AU - Baglin, T. P. AU - Weitz, J. I. AU - Samama, M. M. PY - 2012 DA - 2012// TI - Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines JO - Chest VL - 141 UR - https://doi.org/10.1378/chest.11-2291 DO - 10.1378/chest.11-2291 ID - Garcia2012 ER - TY - CHAP AU - Bayer Pharma, A. G. PY - 2013 DA - 2013// BT - Xarelto® (rivaroxaban) summary of product characteristics ID - Bayer Pharma2013 ER - TY - CHAP PY - 2013 DA - 2013// BT - Xarelto® (rivaroxaban) prescribing information ID - ref4 ER - TY - CHAP PY - 2013 DA - 2013// BT - Pradaxa® (dabigatran etexilate) summary of product characteristics ID - ref5 ER - TY - CHAP PY - 2012 DA - 2012// BT - Pradaxa® (dabigatran etexilate) prescribing iInformation ID - ref6 ER - TY - CHAP PY - 2012 DA - 2012// BT - Eliquis® (apixaban) summary of product characteristics ID - ref7 ER - TY - CHAP PY - 2012 DA - 2012// BT - Eliquis® (apixaban) prescribing information ID - ref8 ER - TY - CHAP PY - 2013 DA - 2013// BT - Summary of opinion (post authorisation): Xarelto, rivaroxaban ID - ref9 ER - TY - JOUR AU - Eisenberg, P. R. AU - Siegel, J. E. AU - Abendschein, D. R. AU - Miletich, J. P. PY - 1993 DA - 1993// TI - Importance of factor Xa in determining the procoagulant activity of whole-blood clots JO - J Clin Invest VL - 91 UR - https://doi.org/10.1172/JCI116404 DO - 10.1172/JCI116404 ID - Eisenberg1993 ER - TY - JOUR AU - Weitz, J. I. AU - Hudoba, M. AU - Massel, D. AU - Maraganore, J. AU - Hirsh, J. PY - 1990 DA - 1990// TI - Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors JO - J Clin Invest VL - 86 UR - https://doi.org/10.1172/JCI114723 DO - 10.1172/JCI114723 ID - Weitz1990 ER - TY - JOUR AU - Eriksson, B. I. AU - Quinlan, D. J. AU - Eikelboom, J. W. PY - 2011 DA - 2011// TI - Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism JO - Annu Rev Med VL - 62 UR - https://doi.org/10.1146/annurev-med-062209-095159 DO - 10.1146/annurev-med-062209-095159 ID - Eriksson2011 ER - TY - JOUR AU - Perzborn, E. AU - Strassburger, J. AU - Wilmen, A. AU - Pohlmann, J. AU - Roehrig, S. AU - Schlemmer, K. H. AU - Straub, A. PY - 2005 DA - 2005// TI - In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939– an oral, direct Factor Xa inhibitor JO - J Thromb Haemost VL - 3 UR - https://doi.org/10.1111/j.1538-7836.2005.01166.x DO - 10.1111/j.1538-7836.2005.01166.x ID - Perzborn2005 ER - TY - JOUR AU - Samama, M. M. AU - Guinet, C. PY - 2011 DA - 2011// TI - Laboratory assessment of new anticoagulants JO - Clin Chem Lab Med VL - 49 UR - https://doi.org/10.1515/CCLM.2011.134 DO - 10.1515/CCLM.2011.134 ID - Samama2011 ER - TY - JOUR AU - Kubitza, D. AU - Becka, M. AU - Voith, B. AU - Zuehlsdorf, M. AU - Wensing, G. PY - 2005 DA - 2005// TI - Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct Factor Xa inhibitor JO - Clin Pharmacol Ther VL - 78 UR - https://doi.org/10.1016/j.clpt.2005.06.011 DO - 10.1016/j.clpt.2005.06.011 ID - Kubitza2005 ER - TY - JOUR AU - Perzborn, E. AU - Roehrig, S. AU - Straub, A. AU - Kubitza, D. AU - Misselwitz, F. PY - 2011 DA - 2011// TI - The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor JO - Nat Rev Drug Discov VL - 10 UR - https://doi.org/10.1038/nrd3185 DO - 10.1038/nrd3185 ID - Perzborn2011 ER - TY - JOUR AU - Mueck, W. AU - Eriksson, B. I. AU - Bauer, K. A. AU - Borris, L. AU - Dahl, O. E. AU - Fisher, W. D. AU - Gent, M. AU - Haas, S. AU - Huisman, M. V. AU - Kakkar, A. K. AU - Kälebo, P. AU - Kwong, L. M. AU - Misselwitz, F. AU - Turpie, A. G. G. PY - 2008 DA - 2008// TI - Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in patients undergoing major orthopaedic surgery JO - Clin Pharmacokinet VL - 47 UR - https://doi.org/10.2165/00003088-200847030-00006 DO - 10.2165/00003088-200847030-00006 ID - Mueck2008 ER - TY - JOUR AU - Xu, X. S. AU - Moore, K. AU - Burton, P. AU - Stuyckens, K. AU - Mueck, W. AU - Rossenu, S. AU - Plotnikov, A. AU - Gibson, M. AU - Vermeulen, A. PY - 2012 DA - 2012// TI - Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes JO - Br J Clin Pharmacol VL - 74 UR - https://doi.org/10.1111/j.1365-2125.2012.04181.x DO - 10.1111/j.1365-2125.2012.04181.x ID - Xu2012 ER - TY - JOUR AU - Mueck, W. AU - Lensing, A. W. AU - Agnelli, G. AU - Decousus, H. AU - Prandoni, P. AU - Misselwitz, F. PY - 2011 DA - 2011// TI - Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention JO - Clin Pharmacokinet VL - 50 UR - https://doi.org/10.2165/11595320-000000000-00000 DO - 10.2165/11595320-000000000-00000 ID - Mueck2011 ER - TY - JOUR AU - Kubitza, D. AU - Becka, M. AU - Wensing, G. AU - Voith, B. AU - Zuehlsdorf, M. PY - 2005 DA - 2005// TI - Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects JO - Eur J Clin Pharmacol VL - 61 UR - https://doi.org/10.1007/s00228-005-0043-5 DO - 10.1007/s00228-005-0043-5 ID - Kubitza2005 ER - TY - JOUR AU - Kubitza, D. AU - Becka, M. AU - Roth, A. AU - Mueck, W. PY - 2008 DA - 2008// TI - Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects JO - Curr Med Res Opin VL - 24 UR - https://doi.org/10.1185/03007990802361499 DO - 10.1185/03007990802361499 ID - Kubitza2008 ER - TY - JOUR AU - Weinz, C. AU - Schwarz, T. AU - Kubitza, D. AU - Mueck, W. AU - Lang, D. PY - 2009 DA - 2009// TI - Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans JO - Drug Metab Dispos VL - 37 UR - https://doi.org/10.1124/dmd.108.025569 DO - 10.1124/dmd.108.025569 ID - Weinz2009 ER - TY - JOUR AU - Mueck, W. AU - Becka, M. AU - Kubitza, D. AU - Voith, B. AU - Zuehlsdorf, M. PY - 2007 DA - 2007// TI - Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in healthy subjects JO - Int J Clin Pharmacol Ther VL - 45 UR - https://doi.org/10.5414/CPP45335 DO - 10.5414/CPP45335 ID - Mueck2007 ER - TY - JOUR AU - Samama, M. M. AU - Martinoli, J. L. AU - Le Flem, L. AU - Guinet, C. AU - Plu-Bureau, G. AU - Depasse, F. AU - Perzborn, E. PY - 2010 DA - 2010// TI - Assessment of laboratory assays to measure rivaroxaban – an oral, direct Factor Xa inhibitor JO - Thromb Haemost VL - 103 UR - https://doi.org/10.1160/TH09-03-0176 DO - 10.1160/TH09-03-0176 ID - Samama2010 ER - TY - JOUR AU - Barrett, Y. C. AU - Wang, Z. AU - Frost, C. AU - Shenker, A. PY - 2010 DA - 2010// TI - Clinical laboratory measurement of direct Factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay JO - Thromb Haemost VL - 104 UR - https://doi.org/10.1160/TH10-05-0328 DO - 10.1160/TH10-05-0328 ID - Barrett2010 ER - TY - JOUR AU - Harenberg, J. AU - Marx, S. AU - Weiss, C. AU - Kramer, R. AU - Samama, M. AU - Schulman, S. PY - 2012 DA - 2012// TI - Report of the subcommittee of control of anticoagulation on the determination of the anticoagulant effects of rivaroxaban JO - J Thromb Haemost VL - 10 UR - https://doi.org/10.1111/j.1538-7836.2012.04784.x DO - 10.1111/j.1538-7836.2012.04784.x ID - Harenberg2012 ER - TY - CHAP PY - 2009 DA - 2009// BT - HepTest. Clotting procedures for the quantitative determination of heparin in plasma and whole blood ID - ref27 ER - TY - JOUR AU - Harder, S. AU - Parisius, J. AU - Picard-Willems, B. PY - 2008 DA - 2008// TI - Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications JO - Thromb Res VL - 123 UR - https://doi.org/10.1016/j.thromres.2008.05.010 DO - 10.1016/j.thromres.2008.05.010 ID - Harder2008 ER - TY - JOUR AU - Graff, J. AU - Von Hentig, N. AU - Misselwitz, F. AU - Kubitza, D. AU - Becka, M. AU - Breddin, H. K. AU - Harder, S. PY - 2007 DA - 2007// TI - Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity JO - J Clin Pharmacol VL - 47 UR - https://doi.org/10.1177/0091270007302952 DO - 10.1177/0091270007302952 ID - Graff2007 ER - TY - JOUR AU - Gerotziafas, G. T. AU - Elalamy, I. AU - Depasse, F. AU - Perzborn, E. AU - Samama, M. M. PY - 2007 DA - 2007// TI - In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct Factor Xa inhibitor rivaroxaban JO - J Thromb Haemost VL - 5 UR - https://doi.org/10.1111/j.1538-7836.2007.02429.x DO - 10.1111/j.1538-7836.2007.02429.x ID - Gerotziafas2007 ER - TY - JOUR AU - Samama, M. M. AU - Amiral, J. AU - Guinet, C. AU - Perzborn, E. AU - Depasse, F. PY - 2010 DA - 2010// TI - An optimised, rapid chromogenic assay, specific for measuring direct Factor Xa inhibitors (rivaroxaban) in plasma JO - Thromb Haemost VL - 104 UR - https://doi.org/10.1160/TH10-03-0204 DO - 10.1160/TH10-03-0204 ID - Samama2010 ER - TY - JOUR AU - Harenberg, J. AU - Kramer, R. AU - Giese, C. AU - Marx, S. AU - Weiss, C. AU - Wehling, M. PY - 2011 DA - 2011// TI - Determination of rivaroxaban by different Factor Xa specific chromogenic substrate assays: reduction of interassay variability JO - J Thromb Thrombolysis VL - 32 UR - https://doi.org/10.1007/s11239-011-0622-5 DO - 10.1007/s11239-011-0622-5 ID - Harenberg2011 ER - TY - JOUR AU - Samama, M. M. AU - Contant, G. AU - Spiro, T. E. AU - Perzborn, E. AU - Guinet, C. AU - Gourmelin, Y. AU - Le Flem, L. AU - Rohde, G. AU - Martinoli, J. L. PY - 2012 DA - 2012// TI - Evaluation of the anti-Factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls JO - Thromb Haemost VL - 107 UR - https://doi.org/10.1160/TH11-06-0391 DO - 10.1160/TH11-06-0391 ID - Samama2012 ER - TY - JOUR AU - Lindhoff-Last, E. AU - Samama, M. M. AU - Ortel, T. L. AU - Weitz, J. I. AU - Spiro, T. E. PY - 2010 DA - 2010// TI - Assays for measuring rivaroxaban: their suitability and limitations JO - Ther Drug Monit VL - 32 UR - https://doi.org/10.1097/FTD.0b013e3181f2f264 DO - 10.1097/FTD.0b013e3181f2f264 ID - Lindhoff-Last2010 ER - TY - JOUR AU - Smith, S. A. AU - Comp, P. C. AU - Morrissey, J. H. PY - 2006 DA - 2006// TI - Phospholipid composition controls thromboplastin sensitivity to individual clotting factors JO - J Thromb Haemost VL - 4 UR - https://doi.org/10.1111/j.1538-7836.2006.01848.x DO - 10.1111/j.1538-7836.2006.01848.x ID - Smith2006 ER - TY - JOUR AU - Smith, S. A. AU - Morrissey, J. H. PY - 2007 DA - 2007// TI - Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct Factor Xa inhibitors. [abstract] JO - Blood (ASH Annual Meeting Abstracts) VL - 110 ID - Smith2007 ER - TY - JOUR AU - Siegal, D. M. AU - Crowther, M. A. PY - 2013 DA - 2013// TI - Acute management of bleeding in patients on novel oral anticoagulants JO - Eur Heart J VL - 34 UR - https://doi.org/10.1093/eurheartj/ehs408 DO - 10.1093/eurheartj/ehs408 ID - Siegal2013 ER - TY - JOUR AU - Tripodi, A. AU - Chantarangkul, V. AU - Guinet, C. AU - Samama, M. M. PY - 2011 DA - 2011// TI - The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study JO - J Thromb Haemost VL - 9 UR - https://doi.org/10.1111/j.1538-7836.2010.04106.x DO - 10.1111/j.1538-7836.2010.04106.x ID - Tripodi2011 ER - TY - JOUR AU - Kluft, C. PY - 2012 DA - 2012// TI - A large effects of rivaroxaban in the PT with specifically Simplastin Excel S may be used for diagnostic purposes [abstract] JO - Hämostaseologie VL - 32 ID - Kluft2012 ER - TY - JOUR AU - Samama, M. M. AU - Contant, G. AU - Spiro, T. E. AU - Perzborn, E. AU - Le Flem, L. AU - Guinet, C. AU - Gourmelin, Y. AU - Martinoli, J. L. PY - 2012 DA - 2012// TI - Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial JO - Clin Appl Thromb Hemost VL - 18 UR - https://doi.org/10.1177/1076029611426282 DO - 10.1177/1076029611426282 ID - Samama2012 ER - TY - JOUR AU - Kies, M. S. AU - Posch, J. J. AU - Giolma, J. P. AU - Rubin, R. N. PY - 1980 DA - 1980// TI - Hemostatic function in cancer patients JO - Cancer VL - 46 UR - https://doi.org/3.0.CO;2-L DO - 3.0.CO;2-L ID - Kies1980 ER - TY - JOUR AU - Seifter, E. J. AU - Parker, R. I. AU - Gralnick, H. R. AU - Wesley, M. AU - DeVita, V. T. AU - Young, R. C. AU - Longo, D. L. PY - 1985 DA - 1985// TI - Abnormal coagulation results in patients with Hodgkin's disease JO - Am J Med VL - 78 UR - https://doi.org/10.1016/0002-9343(85)90216-5 DO - 10.1016/0002-9343(85)90216-5 ID - Seifter1985 ER - TY - JOUR AU - Thachil, J. PY - 2008 DA - 2008// TI - Relevance of clotting tests in liver disease JO - Postgrad Med J VL - 84 UR - https://doi.org/10.1136/pgmj.2007.066415 DO - 10.1136/pgmj.2007.066415 ID - Thachil2008 ER - TY - JOUR AU - Mani, H. AU - Rohde, G. AU - Stratmann, G. AU - Hesse, C. AU - Herth, N. AU - Schwers, S. AU - Perzborn, E. AU - Lindhoff-Last, E. PY - 2012 DA - 2012// TI - Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin JO - Thromb Haemost VL - 108 UR - https://doi.org/10.1160/TH11-12-0832 DO - 10.1160/TH11-12-0832 ID - Mani2012 ER - TY - JOUR AU - Asmis, L. M. AU - Alberio, L. AU - Angelillo-Scherrer, A. AU - Korte, W. AU - Mendez, A. AU - Reber, G. AU - Seifert, B. AU - Stricker, H. AU - Tsakiris, D. A. AU - Wuillemin, W. A. PY - 2012 DA - 2012// TI - Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories JO - Thromb Res VL - 129 UR - https://doi.org/10.1016/j.thromres.2011.06.031 DO - 10.1016/j.thromres.2011.06.031 ID - Asmis2012 ER - TY - JOUR AU - Mueck, W. AU - Borris, L. C. AU - Dahl, O. E. AU - Haas, S. AU - Huisman, M. V. AU - Kakkar, A. K. AU - Kälebo, P. AU - Muelhofer, E. AU - Misselwitz, F. AU - Eriksson, B. I. PY - 2008 DA - 2008// TI - Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement JO - Thromb Haemost VL - 100 ID - Mueck2008 ER - TY - JOUR AU - Eikelboom, J. W. AU - Weitz, J. I. PY - 2010 DA - 2010// TI - New anticoagulants JO - Circulation VL - 121 UR - https://doi.org/10.1161/CIRCULATIONAHA.109.853119 DO - 10.1161/CIRCULATIONAHA.109.853119 ID - Eikelboom2010 ER - TY - JOUR AU - Bounameaux, H. AU - Reber, G. PY - 2010 DA - 2010// TI - New oral antithrombotics: a need for laboratory monitoring. Against JO - J Thromb Haemost VL - 8 UR - https://doi.org/10.1111/j.1538-7836.2010.03759.x DO - 10.1111/j.1538-7836.2010.03759.x ID - Bounameaux2010 ER - TY - JOUR AU - Harenberg, J. AU - Du, S. AU - Kramer, S. AU - Giese, C. AU - Schulze, A. AU - Weiss, C. AU - Kramer, R. PY - 2013 DA - 2013// TI - Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples JO - Semin Thromb Hemost VL - 39 ID - Harenberg2013 ER - TY - JOUR AU - Schulman, S. AU - Crowther, M. A. PY - 2012 DA - 2012// TI - How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-10-378950 DO - 10.1182/blood-2011-10-378950 ID - Schulman2012 ER - TY - JOUR AU - Ortel, T. L. PY - 2012 DA - 2012// TI - Perioperative management of patients on chronic antithrombotic therapy JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-05-423228 DO - 10.1182/blood-2012-05-423228 ID - Ortel2012 ER - TY - JOUR AU - Turpie, A. G. G. AU - Kreutz, R. AU - Llau, J. AU - Norrving, B. AU - Haas, S. PY - 2012 DA - 2012// TI - Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor JO - Thromb Haemost VL - 108 UR - https://doi.org/10.1160/TH12-03-0209 DO - 10.1160/TH12-03-0209 ID - Turpie2012 ER - TY - JOUR AU - Huisman, M. V. AU - Lip, G. Y. H. AU - Diener, H. C. AU - Brueckmann, M. AU - van Ryn, J. AU - Clemens, A. PY - 2012 DA - 2012// TI - Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice JO - Thromb Haemost VL - 107 UR - https://doi.org/10.1160/TH11-10-0718 DO - 10.1160/TH11-10-0718 ID - Huisman2012 ER -